Network


Latest external collaboration on country level. Dive into details by clicking on the dots.

Hotspot


Dive into the research topics where Antoon T. M. Willemsen is active.

Publication


Featured researches published by Antoon T. M. Willemsen.


European Journal of Nuclear Medicine and Molecular Imaging | 2010

FDG PET and PET/CT: EANM procedure guidelines for tumour PET imaging: version 1.0

Ronald Boellaard; Michael O'Doherty; Wolfgang A. Weber; Felix M. Mottaghy; Markus N. Lonsdale; Sigrid Stroobants; Wim J.G. Oyen; Joerg Kotzerke; Otto S. Hoekstra; Jan Pruim; Paul Marsden; Klaus Tatsch; Corneline J. Hoekstra; Eric P. Visser; Bertjan Arends; Fred J. Verzijlbergen; Josée M. Zijlstra; Emile F.I. Comans; Adriaan A. Lammertsma; Anne M. J. Paans; Antoon T. M. Willemsen; Thomas Beyer; Andreas Bockisch; Cornelia Schaefer-Prokop; Dominique Delbeke; Richard P. Baum; Arturo Chiti; Bernd J. Krause

The aim of this guideline is to provide a minimum standard for the acquisition and interpretation of PET and PET/CT scans with [18F]-fluorodeoxyglucose (FDG). This guideline will therefore address general information about [18F]-fluorodeoxyglucose (FDG) positron emission tomography-computed tomography (PET/CT) and is provided to help the physician and physicist to assist to carrying out, interpret, and document quantitative FDG PET/CT examinations, but will concentrate on the optimisation of diagnostic quality and quantitative information.


Annals of Neurology | 2005

Blood-brain barrier dysfunction in parkinsonian midbrain in vivo

Rudie Kortekaas; Klaus L. Leenders; Joost C. H. van Oostrom; Willem Vaalburg; Joost Bart; Antoon T. M. Willemsen; N. Harry Hendrikse

Parkinsons disease (PD) is associated with a loss of neurons from the midbrain. The cause of PD is unknown, but it is established that certain neurotoxins can cause similar syndromes. The brain is normally protected from these noxious blood‐borne chemicals by the blood–brain barrier which includes specialized proteins on the inside of blood vessels in the brain. These act as molecular efflux pumps and P‐glycoprotein (P‐gp) is an abundant representative. Vulnerability to PD appears codetermined by the genotype for the P‐gp gene. We hypothesized that PD patients have reduced P‐gp function in the blood–brain barrier. We used positron emission tomography to measure brain uptake of [11C]‐verapamil, which is normally extruded from the brain by P‐gp. Here, we show significantly elevated uptake of [11C]‐verapamil (18%) in the midbrain of PD patients relative to controls. This is the first evidence supporting a dysfunctional blood–brain barrier as a causative mechanism in PD. Ann Neurol 2005;57:176–179


European Journal of Nuclear Medicine and Molecular Imaging | 2015

FDG PET/CT: EANM procedure guidelines for tumour imaging: version 2.0

Ronald Boellaard; Roberto Delgado-Bolton; Wim J.G. Oyen; Francesco Giammarile; Klaus Tatsch; Wolfgang Eschner; Fred J. Verzijlbergen; Sally Barrington; Lucy Pike; Wolfgang A. Weber; Sigrid Stroobants; Dominique Delbeke; Kevin J. Donohoe; Scott Holbrook; Michael M. Graham; Giorgio Testanera; Otto S. Hoekstra; Josée M. Zijlstra; Eric P. Visser; Corneline J. Hoekstra; Jan Pruim; Antoon T. M. Willemsen; Bertjan Arends; Joerg Kotzerke; Andreas Bockisch; Thomas Beyer; Arturo Chiti; Bernd J. Krause

The purpose of these guidelines is to assist physicians in recommending, performing, interpreting and reporting the results of FDG PET/CT for oncological imaging of adult patients. PET is a quantitative imaging technique and therefore requires a common quality control (QC)/quality assurance (QA) procedure to maintain the accuracy and precision of quantitation. Repeatability and reproducibility are two essential requirements for any quantitative measurement and/or imaging biomarker. Repeatability relates to the uncertainty in obtaining the same result in the same patient when he or she is examined more than once on the same system. However, imaging biomarkers should also have adequate reproducibility, i.e. the ability to yield the same result in the same patient when that patient is examined on different systems and at different imaging sites. Adequate repeatability and reproducibility are essential for the clinical management of patients and the use of FDG PET/CT within multicentre trials. A common standardised imaging procedure will help promote the appropriate use of FDG PET/CT imaging and increase the value of publications and, therefore, their contribution to evidence-based medicine. Moreover, consistency in numerical values between platforms and institutes that acquire the data will potentially enhance the role of semiquantitative and quantitative image interpretation. Precision and accuracy are additionally important as FDG PET/CT is used to evaluate tumour response as well as for diagnosis, prognosis and staging. Therefore both the previous and these new guidelines specifically aim to achieve standardised uptake value harmonisation in multicentre settings.


The Journal of Nuclear Medicine | 2009

Neuroinflammation in Schizophrenia-Related Psychosis: A PET Study

Janine Doorduin; Erik F. J. de Vries; Antoon T. M. Willemsen; Jan Cees de Groot; Rudi Dierckx; Hans C. Klein

Schizophrenia is a chronic and disabling brain disease characterized by psychotic episodes with unknown etiology. It is suggested that neuroinflammation plays a role in the pathophysiology of schizophrenia. Neuroinflammation is characterized by the activation of microglia cells, which show an increase in the expression of the peripheral benzodiazepine receptor. The isoquinoline (R)-N-11C-methyl-N-(1-methylpropyl)-1-(2-chlorophenyl)isoquinoline-3-carboxamide (11C-(R)-PK11195) is a peripheral benzodiazepine receptor ligand that can be used for the imaging of activated microglia cells, and thus neuroinflammation, with PET. We hypothesized that neuroinflammation would be more profound in schizophrenic patients during psychosis, and it was therefore investigated whether neuroinflammation was present in patients within the schizophrenia spectrum who were in a psychotic phase. Methods: Seven patients within the schizophrenia spectrum who were recovering from psychosis were included. Recovering psychosis was defined by a score of 5 or more on 1 item of the positive scale of the positive and negative symptoms scale (PANSS) or a score of 4 on 2 items. The patients were compared with 8 age-matched healthy volunteers. Dynamic 60-min PET scans were acquired after the injection of 11C-(R)-PK11195. All subjects underwent T1- and T2-weighted MRI, and the scans were visually examined for abnormalities and used for anatomic coregistration in data analysis. The PET data were analyzed with a 2-tissue-compartment model to calculate the binding potential, using the metabolite-corrected plasma curve as input. Results: A significantly higher binding potential of 11C-(R)-PK11195, indicative of neuroinflammation, was found in the hippocampus of schizophrenic patients than in healthy volunteers (2.07 ± 0.42 vs. 1.37 ± 0.30; P = 0.004). A nonsignificant 30% higher 11C-(R)-PK11195 binding potential was found in the whole-brain gray matter of schizophrenic patients. The MR images did not reveal any visual abnormalities. Conclusion: The present study suggests that focal neuroinflammation may play an important role in schizophrenia during psychosis.


European Journal of Nuclear Medicine and Molecular Imaging | 2008

The Netherlands protocol for standardisation and quantification of FDG whole body PET studies in multi-centre trials.

Ronald Boellaard; Wim J.G. Oyen; Corneline J. Hoekstra; Otto S. Hoekstra; Eric P. Visser; Antoon T. M. Willemsen; Bertjan Arends; Fred J. Verzijlbergen; Josée M. Zijlstra; Anne M. J. Paans; Emile F.I. Comans; Jan Pruim

IntroductionSeveral studies have shown the usefulness of positron emission tomography (PET) quantification using standardised uptake values (SUV) for diagnosis and staging, prognosis and response monitoring. Many factors affect SUV, such as patient preparation procedures, scan acquisition, image reconstruction and data analysis settings, and the variability in methodology across centres prohibits exchange of SUV data. Therefore, standardisation of 2-[18F] fluoro-2-deoxy-D-glucose (FDG) PET whole body procedures is required in multi-centre trials.MethodsA protocol for standardisation of quantitative FDG whole body PET studies in the Netherlands (NL) was defined. This protocol is based on standardisation of: (1) patient preparation; (2) matching of scan statistics by prescribing dosage as function of patient weight, scan time per bed position, percentage of bed overlap and image acquisition mode (2D or 3D); (3) matching of image resolution by prescribing reconstruction settings for each type of scanner; (4) matching of data analysis procedure by defining volume of interest methods and SUV calculations and; (5) finally, a multi-centre QC procedure is defined using a 20-cm diameter phantom for verification of scanner calibration and the NEMA NU 2 2001 Image Quality phantom for verification of activity concentration recoveries (i.e., verification of image resolution and reconstruction convergence).DiscussionThis paper describes a protocol for standardization of quantitative FDG whole body multi-centre PET studies.ConclusionThe protocol was successfully implemented in the Netherlands and has been approved by the Netherlands Society of Nuclear Medicine.


Journal of Neural Transmission | 2008

Decreased blood–brain barrier P-glycoprotein function in the progression of Parkinson’s disease, PSP and MSA

Anna L. Bartels; Antoon T. M. Willemsen; Rudie Kortekaas; B. M. de Jong; R. de Vries; O. de Klerk; J. C. H. van Oostrom; A. Portman; Klaus L. Leenders

Decreased blood–brain barrier (BBB) efflux function of the P-glycoprotein (P-gp) transport system could facilitate the accumulation of toxic compounds in the brain, increasing the risk of neurodegenerative pathology such as Parkinson’s disease (PD). This study investigated in vivo BBB P-gp function in patients with parkinsonian neurodegenerative syndromes, using [11C]-verapamil PET in PD, PSP and MSA patients. Regional differences in distribution volume were studied using SPM with higher uptake interpreted as reduced P-gp function. Advanced PD patients and PSP patients had increased [11C]-verapamil uptake in frontal white matter regions compared to controls; while de novo PD patients showed lower uptake in midbrain and frontal regions. PSP and MSA patients had increased uptake in the basal ganglia. Decreased BBB P-gp function seems a late event in neurodegenerative disorders, and could enhance continuous neurodegeneration. Lower [11C]-verapamil uptake in midbrain and frontal regions of de novo PD patients could indicate a regional up-regulation of P-gp function.


Movement Disorders | 2010

Typical cerebral metabolic patterns in neurodegenerative brain diseases

Laura K. Teune; Anna L. Bartels; Bauke M. de Jong; Antoon T. M. Willemsen; Silvia Eshuis; Jeroen J. de Vries; Joost C. H. van Oostrom; Klaus L. Leenders

The differential diagnosis of neurodegenerative brain diseases on clinical grounds is difficult, especially at an early disease stage. Several studies have found specific regional differences of brain metabolism applying [18F]‐fluoro‐deoxyglucose positron emission tomography (FDG‐PET), suggesting that this method can assist in early differential diagnosis of neurodegenerative brain diseases.


Neurobiology of Aging | 2009

Blood-brain barrier P-glycoprotein function decreases in specific brain regions with aging: A possible role in progressive neurodegeneration

Anna L. Bartels; Rudie Kortekaas; Joost Bart; Antoon T. M. Willemsen; Onno L. de Klerk; Jeroen J. de Vries; Joost C. H. van Oostrom; Klaus L. Leenders

Cerebrovascular P-glycoprotein (P-gp) acts at the blood-brain barrier (BBB) as an active cell membrane efflux pump for several endogenous and exogenous compounds. Age-associated decline in P-gp function could facilitate the accumulation of toxic substances in the brain, thus increasing the risk of neurodegenerative pathology with aging. We hypothesised a regionally reduced BBB P-gp function in older healthy subjects. We studied cerebrovascular P-gp function using [(11)C]-verapamil positron emission tomography (PET) in seventeen healthy volunteers with age 18-86. Logan analysis was used to calculate the distribution volume (DV) of [(11)C]-verapamil in the brain. Statistical Parametric Mapping was used to study specific regional differences between the older compared with the younger adults. Older subjects showed significantly decreased P-gp function in internal capsule and corona radiata white matter and in orbitofrontal regions. Decreased BBB P-gp function in those regions could thus explain part of the vulnerability of the aging brain to white matter degeneration. Moreover, decreased BBB P-gp function with aging could be a mechanism by which age acts as the main risk factor for the development of neurodegenerative disease.


The Journal of Nuclear Medicine | 2007

Chemotherapy Response Evaluation with 18F-FDG PET in Patients with Non-Small Cell Lung Cancer

Lioe-Fee de Geus-Oei; Henricus F. M. van der Heijden; Eric P. Visser; Rick Hermsen; Bas A. van Hoorn; Johanna N. H. Timmer-Bonte; Antoon T. M. Willemsen; Jan Pruim; Frans H.M. Corstens; Paul F. M. Krabbe; Wim J.G. Oyen

The aim of this prospective study was to evaluate the value of 18F-FDG PET for the assessment of chemotherapy response in patients with non–small cell lung cancer. Furthermore, part of the objective of this study was to compare 2 methods to quantify changes in glucose metabolism. Methods: In 51 patients, dynamic 18F-FDG PET was performed before and at 5–8 wk into treatment. Simplified methods to measure glucose metabolism (standardized uptake value [SUV]) and quantitative measures (metabolic rate of glucose [MRGlu]), derived from Patlak analysis, were evaluated. The overall survival and progression-free survival with respect to MRGlu and SUV were calculated using Kaplan–Meier estimates. Fractional changes in tumor glucose use were stratified by the median value and also the predefined EORTC (European Organization for Research and Treatment of Cancer) metabolic response criteria, and criteria applying cutoff levels similar to those of RECIST (Response Evaluation Criteria in Solid Tumors) were evaluated. Results: When stratifying at the median value of ΔMRGlu and ΔSUV, the difference in overall survival (P = 0.017 for ΔMRGlu, P = 0.018 for ΔSUV) and progression-free survival (P = 0.002 for ΔMRGlu, P = 0.0009 for ΔSUV) was highly significant. When applying the predefined criteria for metabolic response, the cutoff levels as also used for size measurement (RECIST) showed significant differences for ΔSUV between response categories in progression-free survival (P = 0.0003) as well as overall survival (P = 0.027). Conclusion: The degree of chemotherapy-induced changes in tumor glucose metabolism as determined by 18F-FDG PET is highly predictive for patient outcome, stratifying patients into groups with widely differing overall survival and progression-free survival probabilities. The use of 18F-FDG PET for therapy monitoring seems clinically feasible, because simplified methods to measure tumor glucose use (SUV) are sufficiently reliable and can replace more complex, quantitative measures (MRGlu) in this patient population.


Methods | 2002

Measuring drug-related receptor occupancy with positron emission tomography

Jan Passchier; Antony D. Gee; Antoon T. M. Willemsen; Willem Vaalburg; Aren van Waarde

Several techniques can be used to measure indirectly the effect of drugs (e.g., EEG, fMRI) in healthy volunteers and in patients. Although each technique has its merits, a direct link between drug efficacy and site of action in vivo usually cannot be established. In addition, when the specific mode of action of a drug has been determined from preclinical studies, it is often not known whether the administered dose is optimal for humans. Both industry and academia are becoming more and more interested in determining the dose-related occupancy of specific targets caused by administration of drugs under test. Positron emission tomography (PET) and single-photon emission computed tomography (SPECT) are noninvasive imaging techniques that can give insight into the relationship between target occupancy and drug efficacy, provided a suitable radioligand is available. Although SPECT has certain advantages (e.g., a long half-life of the radionuclides), the spatial and temporal resolution as well as the labeling possibilities of this technique are limited. This review focuses on PET methodology for conducting drug occupancy studies in humans.

Collaboration


Dive into the Antoon T. M. Willemsen's collaboration.

Top Co-Authors

Avatar
Top Co-Authors

Avatar

Jan Pruim

Stellenbosch University

View shared research outputs
Top Co-Authors

Avatar

Aren van Waarde

University Medical Center Groningen

View shared research outputs
Top Co-Authors

Avatar

Rudi Dierckx

University Medical Center Groningen

View shared research outputs
Top Co-Authors

Avatar

Anne M. J. Paans

University Medical Center Groningen

View shared research outputs
Top Co-Authors

Avatar
Top Co-Authors

Avatar

Ronald Boellaard

University Medical Center Groningen

View shared research outputs
Top Co-Authors

Avatar

Erik F. J. de Vries

University Medical Center Groningen

View shared research outputs
Top Co-Authors

Avatar

Johan A. den Boer

University Medical Center Groningen

View shared research outputs
Top Co-Authors

Avatar

Riemer H. J. A. Slart

University Medical Center Groningen

View shared research outputs
Researchain Logo
Decentralizing Knowledge